Chicago Capital Management, LLC
Long book
$49.4M
Q1 2026
Positions
13
Top-10 weight
99%
concentration
Last quarter
+0.9%
SPY +14.8%
Turnover
81%
of book per quarter
Strategy in plain words
auto-generated from filingsChicago Capital Management, LLC is a concentrated fundamental stock-picker, specialised in industrials (96% of the long book), running a $49.4M US long book across 13 positions.
The portfolio is extremely concentrated — the top 10 positions are almost the whole book. Turnover is high — positions rotate quickly, so individual names matter less than the process. Current anchor positions: CHART INDUSTRIES INC, Janus Hendersongroup Pl, ARCELLX INC, AMICUS THERAPEUTICS INC, APELLIS PHARMACEUTICALS INC.
Over the last 7 quarters its long book ran on average 2.1pp per quarter behind the S&P 500, beating the index in 3 of 7 quarters. We rate its filings as signal-bearing: position changes reflect genuine views.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q1 2024
-18.6%
Q2 2024
+11.0%
Q3 2024
+53.7%
Q4 2024
-19.5%
Q1 2025
-12.4%
Q4 2025
-0.5%
Q1 2026
+0.9%
Sector allocation
Other 79%
Industrials 20%
Technology 1%
Long book by quarter
What does Chicago Capital own?
Q1 2026 13F| Company | Sector | Shares | Value | % of book | Change |
|---|---|---|---|---|---|
| GTLS CHART INDUSTRIES INC | Industrials | 53.0K | $8.3M | 16.7% | New |
| ACLXGBX ARCELLX INC | — | 93.0K | $8.0M | 16.3% | New |
| AM6 AMICUS THERAPEUTICS INC | — | 666.0K | $7.2M | 14.6% | +66.5% |
| APLSUSD APELLIS PHARMACEUTICALS INC | — | 190.0K | $5.8M | 11.7% | New |
| 430 TERNS PHARMACEUTICALS INC | — | 129.2K | $5.1M | 10.4% | New |
| HPE 7.625 09/01/27 HP ENTERPRISE CO | — | 32.9K | $2.1M | 4.3% | Held |
| BVE DIAMOND HILL INVESTMENT GRP | — | 11.3K | $1.5M | 3.0% | New |
| BLFY BLUE FOUNDRY BANCORP | — | 146.0K | $1.5M | 2.9% | +639.9% |
| 8TG THERMON GROUP HOLDINGS INC | — | 30.1K | $1.1M | 2.3% | New |
| EA ELECTRONIC ARTS INC | Technology | 2.0K | $307K | 0.6% | Held |
| DAWNGBX DAY ONE BIOPHARMACEUTICALS I | — | 10.0K | $162K | 0.3% | New |
| XHC HERITAGE COMMERCE CORP | — | 14.0K | $132K | 0.3% | New |
13F filing history
| Period | Form | Filed | Entries | Reported value | Flags | Source |
|---|---|---|---|---|---|---|
| Q1 2026 | 13F-HR | Apr 27, 2026 | 29 | $120.7M | canonical | SEC ↗ |
| Q4 2025 | 13F-HR | Feb 2, 2026 | 43 | $146.9M | canonical | SEC ↗ |
| Q3 2025 | 13F-HR | Nov 7, 2025 | 28 | $111.8M | canonical | SEC ↗ |
| Q2 2025 | 13F-HR | Aug 7, 2025 | 40 | $136.1M | canonical | SEC ↗ |
| Q1 2025 | 13F-HR | May 9, 2025 | 47 | $160.9M | canonical | SEC ↗ |
| Q4 2024 | 13F-HR | Feb 12, 2025 | 48 | $162.0M | canonical | SEC ↗ |
| Q3 2024 | 13F-HR | Nov 8, 2024 | 41 | $149.6M | canonical | SEC ↗ |
| Q2 2024 | 13F-HR | Aug 14, 2024 | 41 | $129.3M | canonical | SEC ↗ |
| Q1 2024 | 13F-HR | May 9, 2024 | 34 | $95.0M | canonical | SEC ↗ |